Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped

As Arbitration Disappoints

Apr 08 2022

• By Ayisha Sharma

Law mallet and a stack of money — Darzalex Made Over $6bn In 2021 Sales • Source: Alamy

Related Content

Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared

Sep 25 2021

Genmab Commercial Expansion Opens The Door To New Types Of Deals

Feb 09 2021

Genmab To Expand Proprietary Pipeline, Closing In On Marketing Its Own Products

Aug 12 2021

Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa

Mar 15 2022

Related Companies

Genmab A/S

Johnson & Johnson

Sanofi

Halozyme Therapeutics, Inc.

Additional Topics

Companies Legal Issues Commercial Research & Development Cancer BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window